<DOC>
	<DOCNO>NCT02225470</DOCNO>
	<brief_summary>This study design open-label randomized parallel two-arm multicenter efficacy , pharmacokinetics safety study intravenously administer eribulin versus intravenously administer vinorelbine Chinese population . Eligible female subject measurable disease accord RECIST 1.1 modification chest x-ray use assessment disease .</brief_summary>
	<brief_title>Eribulin Versus Vinorelbine Subjects With Locally Recurrent Metastatic Breast Cancer Previously Treated With Anthracyclines Taxanes</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion include study . 1 . Female subject histologically cytologically confirm carcinoma breast : 2 . Subjects locally recurrent metastatic disease receive least two , maximum five , prior chemotherapeutic regimen breast cancer , least two administered treatment locally recurrent metastatic disease . Prior therapy must document follow criterion prior entry onto study : 1 . Regimens must include anthracycline ( e.g. , doxorubicin , epirubicin ) , taxane ( e.g. , paclitaxel , docetaxel ) combination order . Prior treatment agent require agent contraindicate prospective subject document medical history . 2 . Some regimen may administer adjuvant and/or neoadjuvant therapy , least two must give locally recurrent metastatic disease . 3 . Subjects must prove refractory recent chemotherapy document progression within 6 month last chemotherapy . 4 . Subjects Her2/neu positive tumor may also treat Her2/neu targeted agent include antibody , small compound investigational drug . 5 . Subjects may also treat antihormonal therapy . 3 . Have measurable disease meeting follow criterion : 1 . At least one lesion great equal 1.0 cm long diameter nonlymph node , great equal 1.5 cm shortaxis diameter lymph node serially measurable accord RECIST 1.1 use computerize tomography/magnetic resonance imaging ( CT/MRI ) . If one target lesion nonlymph node , long diameter great equal 1.5 cm . 2 . Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ( RF ) ablation must show evidence progressive disease base upon RECIST 1.1 use target lesion . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 . 5 . Life expectancy great equal 3 month . 6. subject great equal 18 year old Age le equal 70 year old time inform consent . 7 . Adequate renal function evidence serum creatinine less equal 2.0 mg/dL calculate creatinine clearance great equal 40 mL/min per Cockcroft Gault formula . 8 . Adequate bone marrow function evidence absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L , hemoglobin great equal 10.0 g/dL , platelet count great equal 100 x 10^9/L . 9 . Adequate liver function evidence bilirubin less equal 1.5 time upper limit normal ( ULN ) ; alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3.0 time ULN ( case liver metastases less equal 5.0 time ULN ) . 10 . Subject willing able comply study protocol duration study . 11 . All female subject consider childbearing potential unless postmenopausal ( least 12 month consecutive amenorrhea , appropriate age group without know suspected cause ) , sterilize surgically ( i.e. , bilateral tubal ligation great equal 1 menstrual cycle prior randomization , undergone hysterectomy and/or bilateral oophorectomy ) . Female subject childbearing potential must agree use two form highly effective contraception last menstrual period prior randomization ( use double barrier method describe two form highly effective contraception least one menstrual cycle ) , study treatment , 3 month final dose study treatment . Female subject exempt requirement subject practice total abstinence . If currently abstinent , subject must agree use double barrier method contraception , i.e . condom occlusive cap ( diaphragm cervical/vault cap ) spermicide two form highly effective contraception least one menstrual cycle become sexually active study treatment 3 month final dose study treatment . Highly effective contraception include : 1 . Placement intrauterine device system , 2 . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicide , 3 . Established hormonal contraceptive method : oral , injectable implant . Female subject use hormonal contraceptive must stable dose hormonal contraceptive product last menstrual period prior randomization , must continue use hormonal contraceptive product study treatment , 3 month final dose study treatment , 4 . Vasectomized partner confirm azoospermia . 12 . Voluntary agreement provide write informed consent willingness ability comply aspect protocol , understanding patient may withdraw consent time without prejudice . Exclusion Criteria Subjects meet follow criterion exclude study : 1 . Subjects receive follow treatment within specified period treatment start : 1 . Vinorelbine administrate neoadjuvant adjuvant therapy within one year . 2 . Chemotherapy , radiation , Her2/neu target agent include trastuzumab hormonal therapy within three week . 3 . Any investigational drug within four week . 4 . Blood transfusion , blood preparation hematopoietic factor preparation GCSF within two week . 2 . Subjects advance breast cancer vinorelbine effective therapy CR/PR/SD , PD occur vinorelbine discontinuing within 6 month . 3 . Subjects ineffective prior vinorelbine treatment . 4 . Pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen . 5 . Subjects brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least four week start treatment study . Any sign ( e.g. , radiologic ) and/or symptom brain metastasis must stable least four week start study treatment ; radiographic stability determine compare contrastenhanced CT MRI brain scan perform screen prior scan perform least four week earlier . 6 . Subjects meningeal carcinomatosis . 7 . Woman must pregnant documented negative betahuman chorionic gonadotropin ( betahCG ) test minimum sensitivity 25 IU/L , equivalent unit betahCG , Screening Baseline ; breastfeed . 8 . Severe/uncontrolled intercurrent illness/infection . 9 . Significant cardiovascular impairment ( history congestive heart failure great New York Heart Association ( NYHA ) Class II , unstable angina myocardial infarction within past six month , serious cardiac arrhythmia ) . 10 . Subjects organ allograft require immunosuppression therapy . 11 . Subjects know positive HIV status . 12 . Subjects prior malignancy , breast cancer , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat least five year previously subsequent evidence recurrence . 13 . Subjects preexist neuropathy great Grade 2 . 14 . Subjects hypersensitivity halichondrin B and/or halichondrin B chemical derivative . 15 . Subjects participate prior eribulin clinical trial whether eribulin receive . 16 . Known intolerance eribulin vinorelbine ( excipients ) . 17 . Any medical condition investigator 's opinion may preclude subject enter study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Locally Recurrent Metastatic Breast Cancer</keyword>
</DOC>